Autres langues Better Therapeutics, Inc.

Actions

BTTX

US08773T1043

Marché Fermé - OTC Markets Autres places de cotation 21:50:49 25/04/2024			Varia. 5j.	Varia. 1 janv.
0,009 ^USD	+15,68 %		+12,50 %	-95,38 %

21/03	Better Therapeutics, Inc. reçoit une notification de défaut de la part de Hercules Capital, Inc	CI
14/03	Mise à jour sectorielle : Les actions du secteur de la santé en baisse jeudi après-midi	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	21/03
Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index	20/03
Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from NASDAQ Composite Index	15/03
Sector Update: Health Care Stocks Lower Thursday Afternoon	14/03
Better Therapeutics to Terminate Employees, Explore Strategic Alternatives; Shares Drop Sharply	14/03
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq	14/03
Better Therapeutics : Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq - Form 8-K	14/03
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers	05/03
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)	04/03
Transcript: Better Therapeutics CEO Interview with RedChip - Form 8-K	04/03
Better Therapeutics' Platform Targeting Advanced Liver Disease Receives FDA Breakthrough Device Designation	20/02
Better Therapeutics Gets Breakthrough Device Designation For Cognitive Behavioral Therapy Platform	20/02
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease	20/02
Better Therapeutics, Inc. Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease	20/02
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment	06/02
Better Therapeutics, Inc. announced that it has received $0.25 million in funding	23/01
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone	17/01
Better Therapeutics Inc. Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx Is More Effective and Less Costly Than Standard of Care Alone	17/01
Better Therapeutics, Inc. announced that it expects to receive $0.25 million in funding	05/01
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States	03/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Better Therapeutics, Inc.

Actions

BTTX

US08773T1043

Autres langues

Filtres